Progressive Disseminated Histoplasmosis on Infliximab — Where the Severity Line Actually Sits
A single patient, on a biologic that predisposed him to this exact infection. The disagreement was never really about the antifungal choice — it was about correcting the wrong reason everyone assumed for it.
B.F., a 55-year-old man, inspects residential foundations and crawlspaces for a living, the kind of work that puts him under houses with decades of bird and bat droppings more often than he's ever thought to mention to a doctor. He has rheumatoid arthritis, managed for four years on infliximab alongside a stable low-dose methotrexate regimen that had kept his joints functional enough to keep working. Over the past six weeks he has lost eighteen pounds without trying, run intermittent fevers he attributed to a lingering cold, and only came in when his wife noticed he looked pale enough to mention it. Labs told a story his fatigue alone hadn't: pancytopenia, with a hemoglobin of 8.1 and a platelet count under 60,000, and imaging showed both an enlarged liver and spleen.
A bone marrow biopsy and urine Histoplasma antigen both confirmed progressive disseminated histoplasmosis — the diagnosis his crawlspace work had quietly set up months before symptoms started, and the one anti-TNF therapy is specifically described to predispose toward, since TNF-alpha plays a real role in maintaining the granulomas that ordinarily contain this organism. The treatment question that actually divides the team isn't about infliximab or drug interactions, despite an early assumption that it might be — it's about severity classification. The IDSA histoplasmosis guideline draws a real line between mild-moderate disease, which can start on itraconazole alone, and moderately severe to severe disease, which needs liposomal amphotericin B induction first. His pancytopenia and hepatosplenomegaly land him past that line on the guideline's own criteria, even though he is ambulatory, hemodynamically stable, and not in organ failure — a genuinely different clinical picture than "severe" usually conjures, but one the actual threshold, not his overall appearance, is built to classify. He asked, when the diagnosis was explained to him, whether the crawlspaces themselves were now off-limits — a question nobody on the team had a confident answer for yet, since it depends less on today's regimen than on how long infliximab ultimately stays held.
In clinic, drawing the line between moderate and moderately severe
His pancytopenia and hepatosplenomegaly put him past the guideline's own threshold for moderately severe disease, even though he's ambulatory and stable overall. Anti-TNF-associated histoplasmosis specifically has a described worse natural history without adequate induction — I want liposomal amphotericin B for two weeks before we even talk about itraconazole.
I'll take your severity classification — what I won't accept without argument is the twelve-month figure attached to it. He has had functional joints for four years on infliximab, and that has been the difference between working under houses and not working. An untreated flare is not a cosmetic outcome, and "restart the biologic when the antifungal course is finished" quietly converts a treatment duration into a disability duration.
Twelve months is the minimum duration for the histoplasmosis, not a stated waiting period for resuming anti-TNF therapy — those are two different clocks and I think they are being run as one. Give me the actual criterion for restart, and if it turns out to be response plus adequate drug exposure rather than a completed course, then the answer for him is months earlier than what you just described.
Worth correcting something before we finalize the plan — I'd initially assumed the amphotericin B preference was partly about avoiding an itraconazole-methotrexate interaction, but that interaction is minimal, not a real pharmacokinetic driver here. The actual reason is the severity threshold you named, not a drug interaction. And to answer what you just asked for directly, since it's a fair demand: the criterion I'd hold to isn't a completed course, it's documented clinical and antigen response plus a confirmed therapeutic itraconazole trough. Absorption on itraconazole is inconsistent enough that "started the drug" and "adequately treated" aren't the same statement without a level — which is exactly why a calendar date is the wrong gate. Meet those two conditions and the restart conversation is legitimately open well before month twelve; miss the trough and it isn't open at month twelve either.
Agreed: liposomal amphotericin B induction for two weeks, then itraconazole consolidation for a minimum of twelve months with a confirmed therapeutic trough before infliximab is reconsidered — a plan all three specialties signed off on once the severity-versus-interaction distinction was corrected.
Fully resolved for the antifungal decision itself. The only item explicitly carried forward is scheduling: the rheumatologist will reassess RA disease activity at the twelve-month mark alongside the itraconazole trough, rather than either decision being made in isolation from the other.